Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CUDC-907 in Advanced Thyroid Cancer
NCT03002623Phase 2Terminated
- Sponsor
- National Cancer Institute
- Start
- Dec 2016
- Primary completion
- Feb 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of fimepinostat in thyroid cancer, sponsored by National Cancer Institute. Primary endpoint: Number of Participants With a Clinical Response (Complete Response (CR) + Partial Response (PR)) at 6 months. Started Dec 2016; status: terminated.
02
Drugs
fimepinostat
03
Conditions
thyroid cancer
Beyond the preview
Go deeper on NCT03002623.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03002623.